The effects of tibolone

References

• Stampfer M. J., Colditz C. A. Estrogen replacement therapy and coronary heart disease. A qualitative assessment of the epidemiologic evidence. Prevent Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90: 107–10, Consensus Development Conference
   PubMed Web of Science ®Google Scholar
• Birge S. J., Mortel K. F. Estogens and the treatment of Alzheimer's disease. Am J Med 1997; 103(3A)365–455
   Google Scholar
• Potter J. D. Hormones and colon cancer. J Natl Cancer Inst 1995; 87: 1039–40
   PubMedGoogle Scholar
• Ryan P., Harrison R., Blake G. M., et al. Compliance with HRT after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992; 99: 355–8
   PubMedGoogle Scholar
• Van der Vies J. Pharmacological studies with OD14. Maturitas 1987, Suppl 1: 15–24
   PubMed Web of Science ®Google Scholar
• Herschberger L. G., Shipley E. G., Meryer R. H. Myotrophic activity of 19-nortestosterone and other steroids determined by the modified levator muscle method. Proc Soc Exp Biol Med 1953; 83: 175–80
   PubMed Web of Science ®Google Scholar
• Markiewicz L., Gurpide E. In vitro evaluation of estrogenic, estrogenic antagonistic and progestagenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990; 35: 535–41
   PubMedGoogle Scholar
• Rymer J., Chapman M. G., Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314–17
   PubMed Web of Science ®Google Scholar
• Lindsay R., McKay-Hart D., Kraszawski A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br Med J 1980; 1209–1209
   Google Scholar
• Kicovic P. M., Cortes-Prieto J., Luisi M., et al. Placebo controlled cross-over study of the effects of Org OD14 in postmenopausal women. Reproduction 1982; 6: 81–91
   Google Scholar
• Tax L., Goorissen E. M., Kicovic P. M. Clinical profile of Org OD14. Maturitas 1987, Suppl 1: 3–13
   PubMed Web of Science ®Google Scholar
• Volpe A., Facchinett F., Grasso A. Benefits and risks of different hormonal replacement therapies in postmenopausal women. Maturitas 1986; 8: 327–34
   PubMed Web of Science ®Google Scholar
• Milner M. H., Sinnott M. M., Cooke T. M., et al. A two year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996; 87: 593–9
   PubMed Web of Science ®Google Scholar
• Rymer J., Chapman M. G., Fogelman I., et al. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994; 18: 127–33
   PubMed Web of Science ®Google Scholar
• Sherwin B., Gelfand M., Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47: 339–51
   PubMed Web of Science ®Google Scholar
• Nathorest-Boos J., Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol—norethisterone acetate regimen. Maturitas 1997; 26: 15–20
   PubMed Web of Science ®Google Scholar
• Nathorst-Boos Wiklund I., Mattson L. A., et al. Is sexual life influenced by transdermal oestrogen therapy — a double-blind controlled study in postmenopausal women. Acta Obstet Gynecol Scand 1992; 72: 656–60
   Web of Science ®Google Scholar
• Genazzani A. R., Benedeck-Jaszman L. J., Hart D. M., et al. Org OD14 and the endometrium. Maturitas 1991; 13: 243–51
   PubMed Web of Science ®Google Scholar
• Visser J., deCoert A., Feenstrah, et al. Endocrinological studies with Org OD14. Arzneimittelforsch/ Drug Res 1984; 34: 1010–17
   PubMed Web of Science ®Google Scholar
• Meuwissen J. H., Wiegerinck M. A., Haverkorn M. J. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995; 21: 121–5
   PubMed Web of Science ®Google Scholar
• De Aloysio D., Fabiani A. G., Mauloni M., et al. Use of Org OD14 for the treatment of climacteric complaints. Maturitas 1987, Suppl 1: 49–65
   PubMed Web of Science ®Google Scholar
• Bjarnason N. H., Bjarnason K., Haarbo J., et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82: 1752–6
   PubMed Web of Science ®Google Scholar
• Walker I. D., Davidson J. F., Richards A., et al. The effects of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in menopausal women. Thromb Haemostat 1985; 53: 303–5
   PubMed Web of Science ®Google Scholar
• Rymer J., Crook D., Sidhu M., et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993; 128: 259–62
   PubMedGoogle Scholar
• Farish E., Barnes J. F., Rolton H. A., et al. Effects of tibolone on lipoprotein(a) and HDL subtractions. Maturitas 1994; 20: 215–19
   PubMed Web of Science ®Google Scholar
• Haenggi W., Lippuner K., Riesen W., et al. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997; 104: 708–17
   PubMedGoogle Scholar
• Feher M. D., Cox A., Levy A., et al. Short-term blood pressure and metabolic effects of tibolone in postmenopausal women with MIDDM. Br J Obstet Gynaecol 1996; 103: 281–3
   PubMedGoogle Scholar
• Austin M. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2–14
   PubMed Web of Science ®Google Scholar
• Hardiman P., Nihoyannopoulous P., Kicovic P., et al. Cardiovascular effects of Org OD14 - a new steroidal therapy for climacteric symptoms. Maturitas 1991; 13: 235–42
   PubMed Web of Science ®Google Scholar
• Haenggi W., Linder H. R., Birkhauser M. H., et al. Microscopic findings of the nail-fold capillaries — dependence on menopausal status and HRT. Maturitas 1995; 22: 37–46
   PubMed Web of Science ®Google Scholar
• Crona N., Silvfverstolpe G., Samsoine G. A double blind cross-over study on the effects of ORG 0014 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol (Copenh) 1983; 102: 451–5
   PubMedGoogle Scholar
• Cagnaci A., Mallus E., Tuveri F., et al. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997; 82: 251–3
   PubMed Web of Science ®Google Scholar
• Geusens P., Dequeker J., Gielen J., et al. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991; 13: 155–62
   PubMed Web of Science ®Google Scholar
• Studd J., Arnala I., Zambhere P., et al. Tibolone increases bone mass in women with previous fractures in a placebo controlled bicentre study. Osteoporosis Int 1996, 6(Suppl 1): 230
   Google Scholar
• Bjarnason N. H., Bjarnason K., Haarbo J., et al. Tibolone: prevention of bone loss in late menopausal women. J Clin Endocrinol Metab 1997; 81: 2419–22
   Web of Science ®Google Scholar
• Chetrite G., Kloosterboer H. J., Pasqualini J. R. Effect of tibolone and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997; 17: 135–40
   PubMed Web of Science ®Google Scholar
• Gompel A., Kandouz M., Siromachkova A., et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997; 11(Suppl 1)77–9
   Google Scholar
• Kloosterboer H. J. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumours. Gynecol Endocrinol 1997; 11(Suppl 1)63–8
   Google Scholar
• Rymer J., Fogelman I., Chapman M. G. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994; 101: 53–6
   PubMedGoogle Scholar
• Andrews W. C. Continuous combined estrogen/progestogen hormone replacement therapy. Clin Therap 1995; 17: 815–26
   Web of Science ®Google Scholar
• Von Dadelszen P., Gillmer M. D., Gray M. D., et al. Endometrial hyperplasia and adenocarcinoma during tibolone therapy. Br J Obstet Gynaecol 1994; 101: 158–61
   PubMedGoogle Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and HRT: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–1059
   PubMed Web of Science ®Google Scholar
• Taskin O., Uryan I., Yalcinoglu Al, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997; 67: 40–5
   PubMed Web of Science ®Google Scholar
• Lindsay P. C., Shaw R. W., Coelingh Bennink H. J., et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the GnRHa triptorelin. Fertil Steril 1996; 65: 342–8
   PubMed Web of Science ®Google Scholar
• Compston J. E., Yamaguchi K., Croucher P. I., et al. The effects of GnRHa on iliac crest cancellous bone structure in women with endometriosis. Bone 1995; 16: 261–267
   PubMed Web of Science ®Google Scholar